Cetuximab for Elderly Patients With mCRC

Inclusion Criteria: * Patient has given written informed consent before any trial specific treatment * Histological proven diagnosis of colorectal cancer, metastatic or inoperable advanced, not amenable to curative therapy * Measurable disease, defined as at least one lesion (outside of irradiated areas) that can be measured in at least one dimension as ≥ 10 mm (≥ 15 mm in case of lymph nodes) according to RECIST v1.1 * Tumour with wild-type KRAS and wild-type BRAF gene * No previous systemic chemotherapy for metastatic disease (previous adjuvant chemotherapy is allowed if completed \>6 months before randomization, previous rectal radio-chemo therapy if completed \>1 month before randomization) * WHO performance status 0 or 1 * Age \>75 years; or: age ≥ 70 years with at least one of the following factors: * Any functional dependence as measured by Instrumental Activities of Daily Life (IADL). Significant comorbidity according to the Cumulative Illness Rating Scale for geriatric patients (CIRS-G; any severe comorbidity \> grade 3 or a total score \> 5 qualifies) * Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L * Bilirubin ≤ 2.0 x Upper Limit of Normal (ULN) (unless known Gilbert-Meulengracht syndrome), aspartate aminotransferase (AST)\<2.5xULN * Calculated creatinine clearance ≥ 30 ml/min. (according to the formula of Cockcroft-Gault) * Patient is able to swallow oral medication * Baseline Quality of Life forms have been completed Exclusion Criteria: * Documented or sus…